fashion -WSS

fashion

author：focus 2025-09-07 13:58:10 - browse：54792

A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and Drug Administration said ahead of an advisory committee meeting Thursday to determine whether the drug should remain on the market.

The treatment, Lumakras, is designed to treat lung cancer caused by a specific genetic mutation to a protein called KRAS. It’s one of the most common genetic mutations in cancer, but repeated clinical trial failures had led researchers to deem it “undruggable” until a glimmer of hope came about a decade ago.

Lumakras received an accelerated, or conditional, approval in May 2021, making it the first KRAS drug on the market. Now, the drug’s manufacturer, Amgen, needs to prove it works.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Organ aging and disease risk measured by new blood test

WSS

Biden jokes that Republicans may impeach him because inflation is starting to cool down

Trader Joe's recalls 10K cases of broccoli cheddar soup over potential foreign material

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

'The boss' wants server deleted: New allegations emerge in Trump indictment

Organ aging and disease risk measured by new blood test

hotspot

fashion

leisure time

Activists slam private health insurers over coverage restrictions

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Peter Hotez and the public health issue of online harassment

Organ aging and disease risk measured by new blood test

Medical leaders decry Supreme Court decision on affirmative action

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

Wildfire smoke exposes gaps in outdoor worker protections

With clinical trial data readouts, here's how to spot spin

As demand for Covid shots wanes, Moderna seeks its next success

An outrageous hospital charge: I paid $710 for an hour of babysitting

knowledge

Behind warning on Apellis’s eye drug lies a conflict of interest

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

J&J to emphasize cancer drugs, stop much of its vaccine research

As the dark side of IVF slowly comes into focus, even more transparency is needed

Timeline: Special counsel's probe into Trump's handling of classified documents

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

knowledge

focus

focus

explore